Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
AVAvadel Pharmaceuticals plc logo

Avadel Pharmaceuticals plc (AVDL)

NASDAQ Global Market · Currency in USD
$21.64 ▲ +0.00 (+0.00%)
As of Feb 13, 9:30 AM ET. Market open.

Summary

Previous Close
$21.64
Open
$21.64
Day's Range
$21.64 – $21.64
52 Week Range
$6.38 – $23.57
Volume
35,016,239
Avg. Volume
2,415,222
Market Cap
$2.12B
Beta (5Y Monthly)
1.31
PE Ratio (TTM)
215.97
EPS (TTM)
$0.10
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.43

Profile: Avadel Pharmaceuticals plc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
188
CEO
Gregory J. Divis Jr.

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy.

Earnings

DateEst.Actual
Mar 2, 2026$0.08-$0.05Miss
Aug 7, 2025$0.02$0.10Beat
May 7, 2025-$0.07-$0.05Beat
Mar 3, 2025-$0.05-$0.05Beat
Nov 12, 2024-$0.06-$0.03Beat
Aug 8, 2024-$0.17-$0.14Beat

Analyst view

Consensus price target
$21.43 ▼ -1.0%
Range $18.50 – $30.00
Rating: Buy
Buy 57% · Hold 43% · Sell 0%

Get free alerts on AVDL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.